These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 3923777)

  • 1. Evaluation of treatment in typical absence seizures. The roles of long-term EEG monitoring and ethosuximide.
    Blomquist HK; Zetterlund B
    Acta Paediatr Scand; 1985 May; 74(3):409-15. PubMed ID: 3923777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valproic acid versus ethosuximide in the treatment of absence seizures.
    Sato S; White BG; Penry JK; Dreifuss FE; Sackellares JC; Kupferberg HJ
    Neurology; 1982 Feb; 32(2):157-63. PubMed ID: 6798490
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal).
    Callaghan N; O'Hare J; O'Driscoll D; O'Neill B; Daly M
    Dev Med Child Neurol; 1982 Dec; 24(6):830-6. PubMed ID: 6818076
    [No Abstract]   [Full Text] [Related]  

  • 4. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents.
    Posner EB; Mohamed K; Marson AG
    Cochrane Database Syst Rev; 2003; (3):CD003032. PubMed ID: 12917940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is ethosuximide a risk factor for generalised tonic-clonic seizures in absence epilepsy?
    Schmitt B; Kovacevic-Preradovic T; Critelli H; Molinari L
    Neuropediatrics; 2007 Apr; 38(2):83-7. PubMed ID: 17712736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Epilepsy with myoclonic absences].
    Salas Puig J; Acebes A; González C; Tuñón A; Guisasola LM; Lahoz CH
    Neurologia; 1990; 5(7):242-5. PubMed ID: 2126943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence seizures: valproate or ethosuximide?
    Santavuori P
    Acta Neurol Scand Suppl; 1983; 97():41-8. PubMed ID: 6424396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longterm follow-up of childhood epilepsy with absences. I. Epilepsy with absences at onset.
    Dieterich E; Baier WK; Doose H; Tuxhorn I; Fichsel H
    Neuropediatrics; 1985 Aug; 16(3):149-54. PubMed ID: 3930988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethosuximide in the treatment of absence (peptit mal) seizures.
    Browne TR; Dreifuss FE; Dyken PR; Goode DJ; Penry JK; Porter RJ; White BG; White PT
    Neurology; 1975 Jun; 25(6):515-24. PubMed ID: 805382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy.
    Glauser TA; Cnaan A; Shinnar S; Hirtz DG; Dlugos D; Masur D; Clark PO; Capparelli EV; Adamson PC;
    N Engl J Med; 2010 Mar; 362(9):790-9. PubMed ID: 20200383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine.
    Posner EB; Mohamed K; Marson AG
    Seizure; 2005 Mar; 14(2):117-22. PubMed ID: 15694565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Absence seizures in adulthood: four cases].
    Ribacoba Montero R; Salas Puig J; Ferreiro Martín D
    Neurologia; 1994 Jan; 9(1):25-8. PubMed ID: 8161464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of lamotrigine in the treatment of absence epilepsy crises].
    Mauri-Llerda JA; Tejero-Juste C; Iñiguez C; Morales-Asín F
    Rev Neurol; 2001 Feb 1-15; 32(3):247-50. PubMed ID: 11310280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of flunarizine with sodium valproate or ethosuximide in gamahydroxybutyrate induced absence seizures in rats.
    Subramanyam K; David J; Joseph T
    Indian J Exp Biol; 2001 Oct; 39(10):998-1001. PubMed ID: 11883524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative profiles of sodium valproate and ethosuximide on electro-behavioural correlates in gamma-hydroxybutyrate and pentylenetetrazol induced absence seizures in rats.
    Kumaresan S; David J; Joseph T
    Indian J Physiol Pharmacol; 2000 Oct; 44(4):411-8. PubMed ID: 11214495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spectral analysis of the EEG in children during the introduction of antiepileptic therapy with valproic acid.
    Benninger C; Matthis P; Scheffner D
    Neuropsychobiology; 1985; 13(1-2):93-6. PubMed ID: 3929157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproate-ethosuximide combination therapy for refractory absence seizures.
    Rowan AJ; Meijer JW; de Beer-Pawlikowski N; van der Geest P; Meinardi H
    Arch Neurol; 1983 Dec; 40(13):797-802. PubMed ID: 6416232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproic acid (Depakene). A new anticonvulsant agent.
    Lewis JR
    JAMA; 1978 Nov; 240(20):2190-2. PubMed ID: 100622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of tolerance to the anticonvulsant effect of valproate but not to ethosuximide in a rat model of absence epilepsy.
    Wahle H; Frey HH
    Eur J Pharmacol; 1990 May; 181(1-2):1-8. PubMed ID: 2117539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Historical trend toward improved long-term outcome in childhood absence epilepsy.
    Morse E; Giblin K; Chung MH; Dohle C; Berg AT; Blumenfeld H
    Epilepsy Res; 2019 May; 152():7-10. PubMed ID: 30856420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.